Thelansis

Multiple System Atrophy (MSA) Market Outlook Thelansis’s “Multiple System Atrophy (MSA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple System Atrophy (MSA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on t...

  Multiple System Atrophy (MSA) Market Outlook Thelansis’s “Multiple System Atrophy (MSA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multiple System Atrophy (MSA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Multiple System Atrophy (MSA) Overview Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure (cardiovascular and urinary dysfunction), parkinsonism, cerebellar impairment, and corticospinal signs. The etiology of MSA remains unknown, but its pathological hallmark features include the presence of α-synuclein aggregates primarily in oligodendroglia, accompanied by neurodegene...

 Multiple system atrophy (MSA) is a neurodegenerative disorder with a median survival of 6-9 years that is characterised by autonomic failure (cardiovascular and/or urinary), parkinsonism, cerebellar impairment, and corticospinal signs. ·        The incidence of MSA in the United States is estimated at 0.6 cases per 100,000 people per year in the general population giving a current estimate of about 1,900 new cases per year in the USA. ·        A prevalence study in London, UK, gave an age-adjusted figure of 4.4 living cases per 100,000 population at any one time, which would currently translate to about 14,000 living cases in the USA. Thelansis’s “Multiple System Atrophy (MSA) Market Outlook, Epidemiology , Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landsc...